Current Treatment

Biosimilars – Current Treatment – Immunology

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…

Biosimilars – Current Treatment – Oncology

In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…